[A double-blind cross-over trial of a new hypolipidaemic drug (author's transl)].
A double blind cross-over trial has been carried out on the effects of a nicotinic acid compound on 27 patients affected by hyperlipidemia. The subjects have been treated over one year according the following plan: two peroids of 90 days each with the drug and two with placebo. The statistical analysis showed a significant reduction of serum cholesterol triglycerides, phospholipids and total lipids. In 4 patients out of 27, the treatment has not been completed because of drug intollerance.
D000328:Adult; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010743:Phospholipids / Q000097:blood; D010919:Placebos; D014280:Triglycerides / Q000097:blood
D000960:Hypolipidemic Agents; D009539:Nicotinic Acids; D010743:Phospholipids; D010919:Placebos; D014280:Triglycerides; D002784:Cholesterol
Studio in doppio cieco ed in cross-over di un nuovo farmaco ipolipemizzante.